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Side Effects of Corporate Greed: Pharmaceutical 
Companies Need a Dose of Corporate Social 
Responsibility
Martin L. Hirsch*
I. INTRODUCTION
“The point is, ladies and gentleman, that greed . . . for 
lack  of  a  better  word . . .  is  good.  Greed is  right.  Greed 
works.  Greed  clarifies,  cuts  through,  and  captures  the 
essence of the evolutionary spirit.”1
When  it  comes  to  health  care  and  pharmaceuticals, 
greed  is  not  good.   In  the  world  of  health  care,  where 
patients rely on their doctors to do what is best for them, 
there  is  no  place  for  greed.2  Corporate  governance  in 
pharmaceutical  companies  that  focuses  on  the 
shareholder’s  bottom line is  completely  inconsistent  with 
health  care,  medicine  and  access  to  pharmaceuticals, 
where the patient should come first.3  This Article discusses 
how  the  corporate  governance  of  pharmaceutical 
companies  negatively  affects  health  care  and  access  to 
medicine world wide.4
*© 2008 Martin L. Hirsch.
* J.D. California Western School of Law.
11. WALL STREET (Amercent Films 1987).
22. It has long been held that the relationship of patient and physician is 
one  of  trust  and  confidence.  See 36A CAL.  JUR. 3d  Healing  Arts  and 
Institutions § 352.
33. The Hippocratic Oath, a pledge taken by most graduating medical 
students,  states  in  part,  “I  will  apply,  for  the  benefit  of  the  sick,  all 
measures that are required, avoiding those twin traps of overtreatment 
and  therapeutic  nihilism.”  The  Hippocratic  Oath–Modern  Version, 
http://www.pbs.org/wgbh/  nova/doctors/oath_modern.html. (Last  visited 
February 24, 2008). The Hippocratic Oath also states that “[doctors] will 
remember  that  there  is  art  to  medicine  as  wall  as  science,  and  that 
warmth, sympathy, and understanding may outweigh the surgeon’s knife 
or the chemist’s drug.” Id.
44. It notes that corporations are accountable to their shareholders, and 
that stakeholders of the corporation are not protected by corporate law, 
but protected by other regulatory law. In the context of this article the 
argument would be that pharmaceutical companies are accountable to 
their  shareholders’  interests  even  before  their  customers’,  and  if  a 
customer is injured by a product, that customer has a remedy under tort 
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By  adhering  to  the  typical  shareholder  model  of 
corporate  governance,  the  pharmaceutical  companies’ 
ethics5 do not always align with that which a patient might 
expect from their health care provider.6  The shareholder 
model of corporate governance encourages pharmaceutical 
companies  to  maximize  shareholder  profit.   Transversely, 
patients  and  others  seeking  health  benefits  and  medical 
care from the  products  of  the  pharmaceutical  companies 
are  concerned  with  their  own  health  and  well  being.7 
Therefore, a change from the shareholder model approach 
of corporate governance to one which aligns the interests of 
the  company  with  that  of  their  customers  would  better 
serve  the  medical  needs  the  pharmaceutical  companies’ 
customers.
This Article argues that patient health is good, patient 
health  is  right,  and  that  patient  health  works. 
Pharmaceutical companies should find value in doing what 
is  best  for  patients  rather  than  their  shareholders’  bank 
accounts.   Such  a  system  where  patient  health  is  the 
highest value can be implemented through corporate social 
responsibility8 which  shifts  the  corporations’  duty  from 
maximizing  shareholder  profits  to  considering,  and 
providing for, customer and community needs.  Part I of this 
Article  discusses  several  examples  of  the  effects  of  the 
current corporate governance structure in  pharmaceutical 
companies. Part II examines different international models 
of  corporate  governance,  specifically  looking  at  systems 
promulgated  by  the  United  Nations  and  the  European 
Union.   Part  III  considers  whether  these  systems  of 
corporate social responsibility ultimately provide a means to 
change  the  corporate  governance  of  the  pharmaceutical 
companies in order to recognize health as a fundamental 
law.  Henry  Hansmann  &  Reinier  Kraakman, The  End  of  History  for  
Corporate Law, 89 GEO. L.J. 439 (2001).
55. Ethics, as used here, means the moral conviction to do what is best 
for the patients at all times.
66. Pharmaceutical company refers to companies that produce medicine 
and drugs to treat various diseases, ailments and health issues, and follow 
the shareholder model of corporate governance.
77. See Sacha Bonsor,  Trust  Me I’m a Patient, TIMES (London),  May  1, 
2007, at 4 (stating that patients are led to believe that doctors are right 
about their diagnoses and treatment recommendations).
88. Corporate social responsibility refers to the dedication of businesses 
to the interests of its community, customers, and society at large.
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human right and shift  focus from maximizing shareholder 
profit to maximizing world health.
A. PROFITS VALUED OVER LIVES
A young man sits outside his house in Northern India, 
suffering from the effects of leishmaniasis.  He shows signs 
of fever, has an enlarged spleen, and the whites of his eyes 
are yellow.  This disease will attack his immune system and 
leave him susceptible to infection, most likely tuberculosis. 
If  he is  not  treated,  he will  die.   His  father,  who pulls  a 
rickshaw, worked endlessly to save enough money to save 
his son.  His family has already spent several  months’ of 
income on treatment, only to learn that the treatment they 
worked so hard to acquire would fail.  The drug they could 
afford had lost  its  effectiveness,  and would not  save the 
young man. The drug that doctors formerly used to treat 
the disease had become outdated.9
A  man  in  South  Africa  who  contracted  cerebrospinal 
meningitis during the annual outbreak suffers at home with 
no option for treatment.  His family cannot afford the cost 
for  his  medication,  $65 (USD).   The treatment cost more 
than five wage earners  in  the family  would make in  two 
weeks. The family did not have any money to spare after 
purchasing food and paying for school.10
1. Treating Diseases of the Poor
What  if  Scrooge  had the  power  to  cure  disease,  but 
99. Drug companies stopped researching drugs for tropical diseases such 
as leishmaniasis due to economic reasons, not scientific ones. According 
to pharmaceutical companies there is not a market for medicine that treat 
tropical  diseases.  Tropical  diseases  such  as  malaria  and  leishmaniasis 
effect  people in tropical  areas of  the world,  which are overwhelmingly 
poor areas. There is a market for the medicine in the sense that millions of 
people die from these diseases every year showing how needed the drugs 
are. But there is not a market for these drugs in the sense that the people 
suffering from the diseases are poor and generally could not afford the 
treatment.  Isabel Hilton, A Bitter Pill for the World’s Poor, GUARDIAN, Jan. 5, 
2000, at 20.
010. The author of the article, Mr.  Boudreau, was friends with this sick 
man. The man’s family contacted Mr. Boudreau who took the man to the 
hospital  and paid  the  $65  for  treatment.  After  his  friend received  the 
treatment, the author asked the doctor what would have happened if he 
had not  received treatment.  The doctor’s  response was,  “he would be 
allowed  to  die.”  Ned  Boudreau,  Devil’s  Bargain:  Africa  and  the 
Pharmaceutical  Companies,  ZNET  DAILY COMMENT.,  Oct.  2,  2002, 
http://www.zmag.org/ sustainers/content/2002-10/02boudreau.cfm.
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sacrificed that power in order to maximize profits?11
In the stories told above, and millions others like them 
emanating from the developing world12  poverty is the true 
cause  of  death.13 Either  those  who  contract  the  disease 
cannot afford the treatment,  or  medicine is  not  available 
because  pharmaceutical  companies  stopped  improving 
outdated  drugs.14 Pharmaceutical  companies  have  been 
accused of keeping lifesaving treatment beyond the reach 
of the world’s poor, by keeping prices high, even for drugs 
to treat the poor.15 Even though there is  demand for the 
drugs,  there  is  no  profit  in  producing  them,  so 
pharmaceutical companies have simply stopped.16
Drug  companies  are  criticized  for  focusing  their 
research  on  such  matters  as  baldness,  toe  fungus,  and 
erectile dysfunction rather than global epidemics, especially 
those plaguing poor countries.17 Rather than focus on curing 
life threatening diseases, global pharmaceutical companies 
research  and  produce  what  are  called  lifestyle  drugs, 
because there is far more money to be made selling these 
types of drugs.18 Lifestyle drugs are sold for large profits, 
111. Joseph E. Stiglitz,  Scrooge and Intellectual Property Rights, 333 BRIT. 
MED. J. 1279, 1279 (2006).
212. Developing  countries  are  economically  underdeveloped  countries 
that share the common characteristics of  poverty,  high birthrates,  and 
economic  dependence  on  developed  countries.  See Third  World: 
Definitions  and  Descriptions, 
http://www.thirdworldtraveler.com/General/ThirdWorld_def.  html  (last 
visited Feb. 27, 2008).
313. Hilton, supra note 9, at 1.
414. Id.
515. Oxfam: Drug Firms Waging War on Poor,  CNN.COM,  Feb.  12,  2001, 
http://archives.cnn.com/2001/WORLD/europe/UK/02/12/oxfam.drugs/.
616. The recent trend in pharmaceutical companies is more spending on 
research and development, but production of fewer drugs. The pipeline of 
new drugs is beginning to run out. This is creating a growing urgency to 
find the next blockbuster drug in order to increase profits for the industry 
that a recent estimate found to have lost $1 trillion in future profitability. 
The result of this focus on finding the next blockbuster drug to reverse the 
economic trend is an increased focus on lifestyle drugs that sell for high 
profits  in  the United States,  and a  move away from developing better 
drugs to treat tropical diseases. Billion Dollar Pills, ECONOMIST, Jan. 25, 2007, 
at 70-71.
717. Drugs, such as the ones described above that treat toe fungus and 
baldness, that do not necessarily treat harmful disease, are referred to as 
“lifestyle drugs.” Ken Silverstein, Millions for Viagra, Pennies for Diseases 
of the Poor, NATION, July 19, 1999, at 13.
818. Id.
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whereas  drugs  to  treat  the  poor  amount  to  a  losing 
endeavor because the people who need the drugs cannot 
afford  to  pay  the  high  prices  the  pharmaceuticals 
companies charge in order to maximize profits.19
In 1998, 6.1 million people in developing countries died 
from diseases that are preventable, and curable, including 
malaria,  tuberculosis,  and  lower-respiratory-infections.20 
These people  died because the drugs used to treat  their 
diseases are either no longer effective, nonexistent, or too 
expensive.21 Pharmaceutical  companies  are  currently 
discontinuing their research and development of drugs to 
treat  tropical  diseases  allowing  the  former  treatments  to 
become outdated.22 Of the forty-one important drugs used 
to  treat  tropical  diseases,  diseases  primarily  affecting 
developing countries,  none were discovered in  the 1990s 
and all  but  six  were  discovered before  1985.23  Sleeping 
sickness, a disease that effects 300,000 Africans each year 
can only be treated with the same drug that was used to 
treat it seventy years ago.24  The last drug company that 
made a more effective treatment discontinued the product 
because  it  was  not  profitable.25 The  only  treatment  that 
remains is the seventy-year-old concoction of what amounts 
to  arsenic  and  anti-freeze,  which  kills  5%  of  the  people 
injected with it.26
919. In  2002,  pharmaceutical  companies  that  were  members  of  the 
Fortune  500  out  earned  all  the  other  Fortune  500  companies  by  a 
considerable  margin.  Profits  were  measured  three  ways,  and  in  each 
category the drug companies had higher profits. Measuring profits as a 
percentage of revenue the drug companies earned more by nearly 14%, 
profits as a percentage of assets drug companies earned more by nearly 
12%, and profits as a percentage of equity drug companies earned more 
by over 17%.  NEAL PATTISON & LUKE WARREN, PUB. CITIZEN CONGRESS WATCH, 2002 
DRUG INDUSTRY PROFITS: HEFTY PHARMACEUTICAL COMPANY MARGINS DWARF OTHER INDUSTRIES 
1  (2003),  available  at 
http://www.citizen.org/congree/reform/drug_industry/corporate/ 
articles.cfm?ID=9923.
020. Silverstein, supra note 17, at 13.
121. Hilton, supra note 9, at 1.
222. JEAN O.  LANJOUW &  MARGARET MACLEOD,  STATISTICAL TRENDS IN PHARMACEUTICAL 
RESEARCH FOR POOR COUNTRIES,  2  (2005),  available  at 
http://www.who.int/intellectualproperty/studies/en/Lanjouw_Statistical
%20Trends.pdf.
323. Silverstein, supra note 17, at 14.
424. Donald G. McNeil, Jr., Drug Companies and the Third World: A Case 
Study in Neglect, N.Y. TIMES, May 21, 2000, at 1.
525. Id. at 2.
626. Id.
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2. Generic Drugs and the Fight Against AIDS
“People ask me how we could have been so stupid so as 
to sue Nelson Mandela . . . I say we had to, Mother Theresa 
was already dead.”27
A pharmaceutical company representative told this joke 
at  a  conference  referring  to  the  lawsuit  thirty-nine 
pharmaceutical  companies  brought  to  stop  the  South 
African government from importing cheap antiviral generic 
drugs  to  treat  citizens  infected  with  AIDS  who otherwise 
could not afford treatment.28 The pharmaceutical companies 
eventually dropped the lawsuit, but the drugs remained too 
expensive for the South African government to implement 
an effective treatment program.29
The  world’s  major  pharmaceutical  companies  are 
involved  in  a  similar  fight  against  Brazil  to  stop  its 
production of generic drugs to treat AIDS patients.30  Brazil 
instituted a government funded medical program whereby 
the government would provide free AIDS treatment to those 
who needed it.31 The only way the government could afford 
to continue the program was by producing generic versions 
of the needed drugs.32 Since Brazil instituted the program it 
cut the death rate from AIDS in half.33  The drug companies 
oppose the program because the drugs Brazil produces are 
protected by patents.34
Some  say  the  stance  taken  by  the  pharmaceutical 
companies against providing affordable treatment of AIDS 
shows they value wealth over health.35 The problem facing 
poor countries fighting the AIDS epidemic is the only way to 
727. Amy  Kapcynski, Strict  International  Patent  Laws  Hurt  Developing 
Countries,  YALE GLOBAL,  Dec.  16,  2002,  http://yaleglobal.yale.edu/display. 
article?id=562.
828. Id.
929. Philippe  Riviere,  Patently  Wrong:  Southern  Sickness,  Northern 
Medicine,  LE MONDE DIPLOMATIQUE,  July  2001,  at  1,  http://mondediplo.com/ 
2001/07/07aids.
030. Indira A.R. Lakshmanan, Drug Costs Imperil Brazil AIDS Fight,  BOSTON 
GLOBE, Jan. 3, 2007, at 1, 2.
131. Id. at 1.
232. Id.
333. The Other Drug War: Pharmaceutical Companies and WTO sue Brazil  
and  South  Africa  to  Protect  Prices  and  Patents (Democracy  Now! 
Broadcast  Feb.  15,  2001),  available  at 
http://www.democracynow.org/article.pl?sid=03/ 04/07/0156254.
434. Id. 
535. Oxfam: Drug Firms Waging War on Poor, supra note 15, at 1.
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provide affordable drugs to save lives is to buy or produce 
generic antiviral drugs.36 New antiviral drugs cost $17,000 
(USD) per year, per patient, whereas older generic versions 
of similar treatment cost only hundreds of dollars per year.37 
The option seems to be to either continue producing generic 
treatment and save lives, or switch to patented drugs and 
let the people who cannot afford the treatment to die.38
3. Nigeria Sues Pfizer
The  drug  companies  are  involved  in  another 
international  lawsuit.   This  time,  however,  a  foreign 
government  sued  a  major  drug  company.39 During  an 
outbreak of  meningitis  in 1996, Pfizer provided Trovan to 
treat the disease.40 The Nigerian government sued Pfizer for 
$7 billion (USD) on behalf  of the families of  children who 
died or suffered side effects for alleged unauthorized testing 
636. See The Other Drug War, supra note 33.  See generally Lakshmann, 
supra note 30, at 2.
737. Lakshmanan, supra note 30, at 1.
838. One of the major issues related to the AIDS drugs, as well  as the 
need to provide other types of drugs to poorer nations, are the patent and 
intellectual  property  issues.  To  address  these  issues  the  World  Trade 
Organization (WTO) member countries created an agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS). TRIPS attempt to 
create a balance between the long term goal of providing incentives for 
future  research  and  development  of  new  drugs  by  protecting  patent 
rights, and the short term goal of allowing access to existing, patented, 
drugs  in  order  to  provide  needed  medicine.  The  Doha  Declaration,  in 
which  participating  governments  agreed  on  the  application  of  TRIPS, 
interprets  TRIPS  in  a  way  to  support  public  health.  This  allows 
governments to act in ways that are motivated by the need to protect 
public health. A large part of this is allowing countries the right to grant 
compulsory  licensing  in  an  emergency  situation  to  either  import  or 
produce generic  medicines.  The  countries  have  the  freedom to  decide 
what constitutes an emergency.  See generally TRIPS and Pharmaceutical 
Patents:  Fact  Sheet,  http://www.wto.org/english/tratop_e/ 
trips_e/factsheet_pharm00_e.htm (last visited Feb. 28,  2008);  The Doha 
Declaration  Explained,  http://www.wto.org/english/tratop_e/dda_e/doha 
explained_e.htm#top (last visited Feb. 28, 2008); TRIPS and Public Health, 
Alternative  Law  Forum,  http://www.altlawforum.org/PUBLICATIONS/ 
document.2004-12-18.5846929564 (last visited Feb. 28, 2008) (discussing 
corporate social responsibility, an alternative to TRIPS); infra notes 87–110 
and accompanying text.
939. Faith Jones,  Nigeria Sues Pfizer Over Drug Trial  Scandal, SCIDEV.NET, 
June 6, 2007, http://www.scidev.net/content/news/eng/nigeria-sues-pfizer-
over-drug-trial-scandal.cfm.
040. Nigeria  Sues  Drugs  Giant  Pfizer,  BBC  NEWS,  June  5,  2007,  http:// 
news.bbc.co.uk/2/hi/africa/6719141.stm.
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of Trovan.41 Specifically, the government alleges that Pfizer 
administered Trovan to 233 children, killing 196 of them.42 
Thirty-seven children survived the use of Trovan, but they 
all  suffered  serious  health  problems  such  as  deafness, 
paralysis, brain damage, loss of sight, and slurred speech.43
Pfizer  argues  that  they obtained verbal  consent  from 
parents.44 However,  at  the  time,  Trovan  had  only  been 
approved for use by adults in the United States, and had 
never  been given  to  children.45 Regardless  of  which  side 
wins the lawsuit, it  is clear that children died and Trovan 
caused those deaths.46 Pfizer does not argue that treating 
the  children  with  Trovan  was  an  experiment;  it  instead 
asserts  that  it  had  approval  to  conduct  such  an 
experiment.47 Nonetheless  the  facts  indicate  that  Pfizer 
experimented with those children’s lives.
B. BOTTOM LINE THINKING DOES NOT SPARE U.S. PATIENTS
A fourteen-year-old boy in Michigan rides his skateboard 
outside his parents’ house when he suddenly collapses. He 
had a heart attack. He later died.  The chief pathologist who 
examined  him  concluded  that  the  boy’s  blood  vessels 
showed scarring and tissue growth, commonly associated 
with chronic stimulant use. The medical examiner said that 
ten years of Ritalin use was the likely cause of the gradual 
damage to the boy’s nervous system, ultimately leading to 
his heart attack and his death.48
The  allegations  facing  drug  companies  are  not  only 
coming from abroad. Many stories like the one above have 
surfaced domestically, indicating the trend of valuing profit 
141. Id.
242. Jones, supra note 39.
343. Id.
444. Nigeria Sues Drugs Giant Pfizer, supra note 40.
545. Joe Stephens, Panel Faults Pfizer in ‘96 Clinical Trial in Nigeria, WASH. 
POST, May 7, 2006, at A1.
646. Id.; Jones, supra note 39; Nigeria Sues Drugs Giant Pfizer, supra note 
40.
747. Stephens, supra note 45, at A1.
848. Jeff Levine, Boy’s Death Linked to Ritalin,  WEBMD MED.NEWS, Apr. 18, 
2000,  http://www.webmd.com/news/20000418/boys-death-linked-to-
ritalin;  See  also  Death  from  Ritalin, http://ritalindeath.com/ADHD-Drug-
Deaths.htm (last  visited  Feb.  10,  2008) (memorializing  children  whose 
deaths are linked to using ADD and ADHD treatment drugs such as Ritalin, 
Desipramine, Stratters, and Concerta whose causes of death were either 
heart related or suicide linked to prescription drug use).
MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE AND LEGAL POLICY," 9(2) MINN. J.L. SCI. & 
TECH. 607-636 (2008).
2008] CORPORATE SOCIAL RESPONSIBILITY 615
over public health exists in the United States. This trend is 
most evident in direct-to-consumer advertising,  and over-
prescription of potentially harmful drugs.49
A  2005  report  shows  that  pharmaceutical  companies 
influence doctors’  diagnoses in an effort  to improve their 
bottom  lines.  Researchers  at  Dartmouth  Medical  School 
estimate tens of millions more Americans were diagnosed 
with a sickness or  health problem during the 1990s than 
ever before.50 The criteria used to make a diagnosis have 
been changed in order to classify more healthy people as 
sick.51 Changing  the  criteria  of  what  is  considered  sick 
resulted  in  tens  of  millions  more  customers  for  drug 
companies.52 The  report  uncovered  the  fact  that 
pharmaceutical companies give money to members of the 
World Health Organization, U.S. National Institute of Health 
and some of America’s most prestigious medical societies 
for  these  institutions  to  promote  the  pharmaceutical 
industry’s  agenda.53 As  a  result,  today  three  in  four 
Americans are considered to have at least one disease, but 
millions of these people are truly not sick, resulting in sales 
of drugs to people who do not need them, but can afford to 
pay  for  them.54 Remember:  the  opposite  is  true  in 
developing  countries  where  people  truly  need the  drugs, 
but cannot afford them.
949. See generally Susan Kelleher & Duff Wilson, The Hidden Big Business 
Behind  your  Doctor’s  Diagnosis,  SEATTLE TIMES,  June  26,  2005,  at  A1 
(describing the  influences  of  the  pharmaceutical  industry  on  drug  and 
treatment guidelines).
050. See id.
151. For example, the threshold weight to be considered obese might be 
lowered  by  several  pounds,  or  the  threshold  to  be  diagnosed  with 
hypertension lowered by several blood pressure points. Id.
252. Id.
353. Id. See also Jerry Avorn, Dangerous Deception—Hiding the Evidence 
of Adverse Drug Effects, 355  NEW ENG. J. MED. 2169 (2006). Doctor Avorn 
recalls a conversation with a hospital administrator which illustrates the 
effect  the  pharmaceutical  companies  have  over  doctors,  and  the 
prescriptions  they  write.  Dr.  Avorn  remembered  the  Administrator 
describing how well the hospital’s grand-rounds worked because “the drug 
companies find the speakers, pay their honoraria, and provide free food 
for the doctor which helps a lot with attendance.” Id. Dr. Avorn goes on to 
explain  what  a  good  deal  this  actually  was  for  the  pharmaceutical 
companies, because the doctors who attended would go on to prescribe 
the drugs promoted at that grand-round. Id.
454. Kelleher &Wilson, supra note 49.
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1. Dangerous Side Effects of Commonly Used Drugs 55
Drug  sales  indicate  that  America  is  on  its  way  to 
becoming  a  drug-dependent  nation.  Between  1998  and 
2000,  sales  of  anti-depressant  drugs increased 73%,  and 
sales of analeptics, drugs that stimulate the central nervous 
system like Ritalin and Adderall,  increased 167%.56 British 
drug officials, as well as the Food and Drug Administration, 
warned physicians about the risks associated with the anti-
depressants  Paxil,  which  has  the  potential  to  prompt 
teenagers  and kids  to  consider  suicide.57 Moreover,  there 
are ample documented instances of youth deaths linked to 
Ritalin  and  anti-depressants.58 Nonetheless,  use  of  these 
drugs continue to skyrocket.59
Three independent studies tested the effects of Ritalin 
use in humans. The results of one test concluded that using 
prescription  stimulants  during  childhood  makes  children 
more susceptible to cocaine use as young adults.60 Another 
study found that children treated for ADHD with prescription 
stimulants had a 9% risk of developing psychotic symptoms, 
while  the  control  group—children  who  did  not  use  those 
drugs—showed  zero  signs  of  developing  psychotic 
symptoms.61 A final study found that stimulants can cause 
growth  retardation,  depression  and  obsessive  compulsive 
disorder.62 Critics of the use of stimulants to treat ADHD and 
555. Many commonly  prescribed  drugs  carry  harmful  side  effects.  See 
generally  Avorn,  supra note  53;  Consumers  Union,  Prescription  for 
Change, 
http://www.consumersunion.org/campaigns/prescriptionforchange/004320 
indiv.html (last visited Jan. 30, 2008). To discuss each drug and its side 
effects, however, is beyond the scope of this article.
656. Lou Dobbs, We Need a War vs. Legal Drugs, N.Y. DAILY NEWS, Sept. 28, 
2003, at 14.
757. Id. The diet drug Fen-phen is yet another example of a prescription 
drug  that  manifested  harmful  side  effects  in  its  users.  See David  J. 
Morrow, Fen-phen Maker to Pay Billions in Settlement of Diet-Injury Cases, 
N.Y. TIMES, Oct. 8, 1999, at 1.
858. Death from Ritalin, supra note 48 (describing the deaths of a number 
of children “as a direct result of using psychotropic drugs used for ADD 
and ADHD”).
959. Dobbs, supra note 56.
060. Peter R. Breggin & Fred A. Baughman Jr., Questioning the Treatment 
for ADHD, 291 SCIENCE 595, 595 (2001).
161. Id.
262. Id. See also Gabrielle Weiss & Lily Hechtman, The Hyperactive Child 
Syndrome,  205  SCIENCE 1348,  1348–54  (1979)  (discussing  a  study 
concluding that stimulant drugs can suppress growth and recommending 
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ADD  point  to  the  fact  that  these  stimulants  enhance 
obsessive compulsive behavior while suppressing a child’s 
spontaneous behavior,  such effects are then mistaken as 
improved attention.63
There has also  been an increase in  the use of  statin 
drugs which are used to lower cholesterol  in  adults.64  A 
change  in  the  guidelines  of  what  it  means  to  have high 
blood pressure increased the market for statin drugs.65 Nine 
experts  on  cholesterol  wrote  these  guidelines.66 Of  these 
nine  experts,  six  of  them  have  financial  ties  to  the 
pharmaceutical  companies  that  produce  the  most 
commonly  used  statin  drugs.67 The  more  common  side 
effects  from  statin  drugs  are  liver  damage  and  muscle 
aches.68 Muscle  symptoms  are  the  most  common  side 
effects. This side effect is called “myopathy” and results in 
actual damage to muscle tissue.69 Other less common side 
effects  include  decrease  in  memory  or  concentration, 
depression and irritability, pain other than muscle pain, and 
peripheral neuropathy or tingling and numbness.70
In yet another example of  prescription drugs harming 
their  users,  cyclo-oxygenase-2  (COX  2)  inhibitors  were 
found to be harmful. In 2005, a panel of doctors advised the 
FDA that  all  COX 2  inhibitors  should come with  a  “black 
box” warning that  these drugs increase chances of  heart 
attacks and strokes.71  The most popular COX 2 inhibitors 
are Vioxx,  Celebrex,  and Bextra,  which are  prescribed to 
treat  arthritis.72 A  story  from 2005  estimated  that  Merck 
alone faced nearly 7,000 state and federal lawsuits brought 
lower dosages and periodic breaks in treatment to prevent the side effect 
from occurring).
363. See, e.g., Breggin & Baughman, supra note 60.
464. See generally,  Big Bucks, Big Pharma: Marketing Disease & Pushing 
Drugs,  (Democracy  Now!  broadcast  Jan.  19,  2007),  available  at 
http://www. democracynow.org/article.pl?sid=07/01/19/1432236.
565. Id.
666. Id.
767. Id.
868. The UCSD Statin Study, Statin Adverse Effects, http://medicine.ucsd. 
edu/SES/adverse_effects.htm (last visited Jan. 30, 2008).
969. Id.
070. Id.
171. Leanne Lenzer, FDA Advisers Warn: COX 2 Inhibitors Increase Risk of 
Heart Attack and Stroke, 330 BRIT. MED. J., 440, 440 (2005).
272. Id.
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by people  allegedly  harmed by using  Vioxx.73 Merck,  the 
maker of Vioxx, voluntarily pulled the drug from the shelves 
when it learned that the drug doubled the chance of heart 
attack after eighteen months of use.74
2. Dangers of Direct-to-Consumer Advertising
Aside from changing the guidelines to diagnosis certain 
diseases, drug companies now market not just treatments, 
but  health  conditions  themselves.75  Direct-to-consumer 
advertising  is  defined  as  “any  promotional  effort  by  a 
pharmaceutical  company  to  present  prescription  drug 
information to the general public in the lay media.”76 This 
marketing  normalizes  obscure  disorders,  presenting  the 
conditions  as  common.77 Direct-to-consumer  advertising 
leads people to believe they suffer from certain disorders or 
diseases simply based on the way the advertisement shows 
an uncommon disease in a normal light.78
These drugs certainly help people who truly suffer from 
the  afflictions  they  are  designed  to  treat.  However, 
advertising the drug in a way that makes it seem like these 
diseases  affect  any  person  who  has  felt  shy  in  a  social 
setting, restless at night, or tense, causes people who hear 
the  advertisements  to  worry  that  they  have  a  serious 
disease if they show any of the described symptoms. After 
hearing  an  advertisement,  listeners  will  self-diagnose,  or 
become concerned that they need the drug.79
A  survey  of  people  who  are  exposed  to  direct-to-
consumer advertising revealed that one-quarter of people 
ask their doctors for the actual drug they heard advertised. 
Of  those  people,  three-quarters  received  the  requested 
373. Expert:  Vioxx  Use  Causes  Heart  Attacks,  CBS  NEWS,  Dec.  2,  2005, 
http://www.cbsnews.com/stories/2005/12/02/ap/business/mainD8E8C3V0E
.shtml.
474. Id.
575. See Billion Dollar Pills,  supra note 16, at 71. In America, direct-to-
consumer drug advertising has increased from spending of $1.1 billion in 
1997 to $4.5 billion in 2006. Id.
676. Michael  S.  Wilkes  et  al.  Direct-to-Consumer  Prescription  Drug 
Advertising: Trends, Impact, and Implications, HEALTH AFF., Mar.–Apr. 2000, 
at 110, 112.
777. Big Bucks, Big Pharma, supra note 64.
878. Id. (transcribing a number of typical advertisements).
979. Id.
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prescription from their doctors.80 This effectively means that 
these “patients” prescribed their  own treatment for  what 
they  diagnosed  as  a  medical  condition  requiring  that 
treatment.  As  such  factors  increase  consumer  demand, 
advertising budgets at the pharmaceutical companies also 
increase.81
Direct-to-consumer  advertising  also  reflects  the 
unbalanced  priorities  of  the  companies.  Instead  of 
continuing to develop and research new drugs, as well as 
improve  old  ones,  the  pharmaceutical  companies  spend 
overwhelming  amounts  of  their  budgets  on  advertising.82 
This spending only furthers the need of the pharmaceutical 
companies to search for the next blockbuster drug, instead 
of  developing  more  effective  treatments  for  common 
diseases.83 Related  to  this  issue  is  the  need  of  the 
pharmaceutical companies to extend patent life in order to 
maintain  the  monopoly  on  a  certain  drug.84 In  order  to 
extend  the  patent,  pharmaceutical  companies  will  find  a 
new use for an existing drug.85 Then they market the drug 
for its new use. This marketing requires heavy promotion of 
the drug,86 and further evidences the misalignment between 
the interests of  the pharmaceutical  companies  and those 
who purchase the products they produce.
080. Wilkes et al., supra note 76, at 110–13.
181. Id.
282. PATTISON & WARREN, supra note 19, at 5 .
383. From 1989 through 2000, of the 1,035 new drugs approved only 24% 
were given priority FDA review. This suggests that only those 24% were 
considered  improvements  to  existing  remedies,  because  such  new 
developments  are  commonly given  priority  review.  It  is  likely  that  the 
overwhelming majority of research and development focuses on so called 
“me-too” drugs which are copies of previously successful drugs. Me-too 
drugs cost  much less  to develop because they  involve only tweaks  to 
existing drugs. Thus, the pharmaceutical companies are able to increase 
their spending on advertising, as 76% of their research and development 
goes to drugs that cost less to develop.  Id.
484. A  pharmaceutical  company’s  patent  on  a  certain  drug  creates  a 
monopoly on that drug. This monopoly is quite lucrative, so much so that 
when Eli Lilly’s patent on Prozac was cut short by three years, Lilly’s stock 
dropped  30%  on  the  same  day.  Matthew  Herper,  Drug  Patent  Peril, 
FORBES.COM,  Jan.  26,  2005, 
http://www.forbes.com/technology/2005/01/26/cx_ mh_0126patents.html.
585. Big Bucks, Big Pharma, supra note 64.
686. Id.
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C. A PARADIGM SHIFT FROM A MONETARY BOTTOM LINE TO AN ETHICAL 
BOTTOM LINE
Pharmaceutical  companies  push  unneeded  drugs  to 
those  who  can  afford  them,  and  withhold  desperately 
needed  drugs  from  those  who  cannot  afford  them.  The 
power to cure and save is outweighed by the obligation to 
earn. Ethically,  the corporate structure that mandates the 
responsibility to maximize profits needs to be reformed.
II. CORPORATE SOCIAL RESPONSIBILITY AS THE CURE
Corporate social responsibility (CSR) can cure the ills of 
the pharmaceutical  companies,  because it  will  implement 
new ethics in the corporate structure that recognize broader 
duties beyond those owed to shareholders.
A. DIVERGENT POSITIONS OF CSR
The  corporate  governance  debate  dates  back  to  the 
1930s when Adolf Berle and Merrick Dodd argued whether a 
corporation owes a duty to society as a whole or just to its 
shareholders.87 Berle  argued  that  managers  of  the 
corporation owed a duty to the shareholders because the 
shareholders  own  the  corporation.88 Berle  saw  the 
managers as agents, or trustees, who owed a fiduciary duty 
to the shareholders to maximize shareholder profits.89  Dodd 
held a divergent view, arguing that the corporation should 
focus, not only on the interests of its shareholders, but on 
the interests of its employees, consumers, and the general 
public.90  He noted that public opinion was causing the law 
to change in some areas to a view in which the corporation 
had a duty of social service in addition to profit making.91
The  correlative  modern  views  are  known  as  the 
787. See generally A.A. Berle, Jr., Corporate Powers as Powers in Trust, 44 
HARV. L. REV. 1049 (1931); E. Merrick Dodd, Jr.,  For Whom Are Corporate 
Managers Trustees?, 45 HARV. L. REV. 1145 (1932).
888. Berle,  supra note 87, at 1049 (“It is the thesis of this essay that all 
powers granted to a corporation are necessarily . . . exercisable only for 
the ratable benefit of all shareholders as their interest appears.”).
989. Id.
090. See Dodd, supra note 87, at 1160.
191. Id. (“[T]he law has already reached the point . . . where it compels 
business enterprises to recognize to some extent the interests of other 
persons besides their owners.”).
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standard shareholder-oriented model92 and the stakeholder-
oriented model.93 The standard shareholder-oriented model 
(“shareholder”  model  or  “standard”  model)  adheres  to 
Berle’s  view  that  the  role  of  corporate  managers  is  to 
maximize  shareholder  profits.94 The  stakeholder-oriented 
model  adheres  to  Dodd’s  alternative  construction  of  a 
corporation’s  duty,  expanding  his  argument  to  align  with 
CSR.95
The stakeholder  approach to  corporate governance is 
analogous  to  the  theory  of  CSR.  CSR  focuses  on  the 
communities in which the corporation operates or conducts 
business,  the  environment,  labor  rights,  human  rights  in 
general,  and ethics.96  This  Article focuses on the human 
rights and ethical aspects of CSR. These elements of CSR 
can  change  the  negative  aspects  of  pharmaceutical 
companies discussed in Part I. The goal is to implement CSR 
in the pharmaceutical companies, shifting the corporation’s 
duty  from  a  shareholder  approach  to  a  stakeholder 
approach. Such a major change would shift the focus of the 
pharmaceutical companies to protecting the health of their 
customers  and  providing  necessary  medicine  to  all 
regardless of ability to pay. A change of this sort recognizes 
the specific rights to medicine and health, as well as human 
rights in general.
1. The Standard Shareholder-Oriented Model
The  ethical  responsibility  of  the  pharmaceutical 
companies  is  clear  because  they,  along  with  treating 
physicians, provide treatments to save lives. Yet there are 
many instances of deaths, either because people cannot get 
the right treatment, or they receive the wrong treatment. 
There are further instances of people who receive treatment 
suffering from harmful side effects.  Though pharmaceutical 
292. See  generally Hansmann  &  Kraakman,  supra note  4,  at  440–43 
(discussing the dominance of the standard shareholder-oriented model for 
corporate governance).
393. See Generally Cynthia A. Williams, Corporate Social Responsibility in 
an Era of Economic Globalization, 35 U.C. DAVIS L. REV. 705, 713–14 (2002) 
(discussing various positions of scholars on corporate social responsibility, 
as  well  as  the  stakeholder-oriented  model  providing  insufficient 
accountability).
494. Id. at 708.
595. Id. at 716.
696. Id.
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companies  are  not  solely  to  blame  for  these  issues,  as 
doctors prescribe the medicines that the FDA approves, the 
pharmaceutical companies are most in need of reform due 
to  their  misalignment  of  interests  with  that  of  their 
customers.
Both  the  United  Nations  and  the  World  Health 
Organization  recognize  health  as  a  fundamental  human 
right.97 In that light,  adopting CSR that recognizes human 
rights  would  be  an  effective  means  to  end  the  harmful 
profits-oriented  approach  currently  found  in  the 
pharmaceutical  companies.  The  priority  of  the 
pharmaceutical  companies  must  change from maximizing 
profits to maximizing human health. To undergo this change 
there must be a shift away from the current model which 
solely  requires  the  board  of  directors  to  provide 
shareholders  with  a  fair  return  on  their  investment,  and 
thus requires the board to focus on maximizing profits.98
As seen from the examples discussed in Part I, when the 
pharmaceutical companies strive to maximize profits, they 
fail to always provide ethical health treatment to all those 
who need it. The corporate structure of maximizing profits 
results  in  an  inconsistency  between  the  pharmaceutical 
companies  and  the  expectations  of  those  who  need 
treatment, believe their treatment will make them better, or 
believe that health is a human right.
The common model of corporate governance, the one 
found  in  the  United  States,  and  in  U.S.  pharmaceutical 
companies, is the shareholder model.99 The American Law 
Institute’s Principles of Corporate Governance state that a 
corporation’s objective is to increase corporate profit as well 
as shareholder gain.100 This model of corporate governance 
developed in  the  United  States  as  business  and industry 
grew.101  As their businesses grew, owners could not fully 
797. UNAIDS Joint United Nations Programme on HIV/AIDS, Human Rights, 
http://www.unaids.org/en/PolicyAndPractice/HumanRights/default.asp (last 
visited Feb.  28,  2008);   World Health Organization,  Health and Human 
Rights,  http://www.who.int/hhr/en/ (Last  visited  Feb.  28,  2008)  (“WHO 
Constitution: ‘the enjoyment of the highest attainable standard of health 
is one of the fundamental rights of every human being.’”).
898. Williams, supra note 93, at 717.
999. See Hansmann & Kraakman, supra note 4, at 440–41.
0100.PRINCIPLES OF CORPORATE GOVERNANCE:  ANALYSIS AND RECOMMENDATIONS §  2.01(a) 
(1994).
1101.See Mark  J.  Roe,  Some  Differences  in  Corporate  Structure  in 
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fund  all  their  endeavors,  so  they  sold  shares  of  their 
businesses to any willing purchaser. This model resulted in 
shareholders who were distant from the operations of the 
business.  These  shareholders  lacked the  expertise  in  the 
business to monitor the managers. What developed was a 
system where  the  shareholders  were  not  involved in  the 
operations of the business but were owed a duty to ensure 
the managers were looking after their financial interests.102
The most prevalent form of CSR under the shareholder 
model is to do everything possible, within the confines of 
the law, to maximize shareholder wealth.103 This view relies 
on  contract  and  regulatory  law  to  protect  the  other 
constituencies affected by the corporation.104 This type of 
CSR considers the corporation to have fulfilled its obligation 
to society by bolstering the economy and tax base.105 Thus, 
the shareholder model does not consider it  necessary for 
the  corporation  to  address  other  societal  concerns 
addressed by the stakeholder model of CSR.
2. The Stakeholder Model of CSR
Unlike  the  shareholder  model,  the  stakeholder  model 
mandates  broader  duties  beyond  those  owed  to  share 
owners of the corporation.106 CSR is recognized as a means 
for a company to integrate economic, environmental, and 
social  concerns  while  addressing  both  shareholder  and 
stakeholder  concerns.107 This  definition  embodies  making 
Germany, Japan, and the United States, 102 YALE L.J. 1927, 1933 (1993).
2102.See generally id. at 1936–41 (contrasting the shareholder structure 
in  Germany  and  Japan  with  that  of  the  United  States  in  which 
intermediaries  hold  a  large  percentage  of  shares  which  allows  these 
institutions  to  share  the  power  structure  with  the  corporation  and  its 
managers).
3103.See Williams, supra note 93, at 708.
4104.See id. at 714 (identifying employment contracts, anti-discrimination 
laws, and environmental protection laws, as some of those protections).
5105.See id.
6106.See  generally, Ilias  Bantekas,  Corporate  Social  Responsibility  in 
International Law, 22 B.U. INT’L L.J. 309 (2004) (explaining the sources of 
CER for  multinational  enterprises  in the context  of  a  global  economy); 
Upendra Baxi,  Market  Fundamentalism:  Business  Ethics  at  the Altar  of 
Human Rights, 5 HUM. RTS. L. REV. 1 (2005) (discussing the ramifications of 
the Norms on the Responsibilities of Transnational Corporations and Other 
Business  Enterprises  with  Regard  to  Human Rights  on  businesses  and 
CSR).
7107.See Industry Canada, What is CSR?, http://www.ic.gc.ca/epic/site/csr-
rse.nsf/en/h_rs00094e.html (last visited May 1, 2008).
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decisions not only based on economic factors, but also on 
the  human  rights  and  community  consequences  of  the 
corporation’s actions.108 R. Edward Freemen suggests that 
the corporation owes a duty to individuals or entities who 
affect  or  are  affected  by  corporate  operations.109 He 
recognizes this duty to be equally important to that owed to 
the corporation’s shareholders.110
B. HUMAN RIGHTS AND ETHICAL ASPECTS OF STAKEHOLDER CSR
There are  many international  guidelines  for  CSR.  The 
focus of this Article is those CSR guidelines that recognize 
human rights, ethics and the need for medical treatment.
1. United Nations
The United Nations (UN) Global  Compact (the “Global 
Compact”) is a voluntary global governance111 program that 
focuses  on  implementing  principles  of  CSR.  The  Global 
Compact promotes CSR through ten universal principles of 
human rights, labor, and the environment.112 The idea of the 
Global Compact is to bring together UN agencies and civil 
society  to  support  environmental  and  social  principles.113 
The Global Compact comprises ten principles, two of which 
focus on human rights.114 The principles of the UN Global 
Compact  are  derived  from  the  Universal  Declaration  of 
Human Rights (UDHR).115 Article 25 of the UDHR states:
Everyone has the right to a standard of living adequate for the 
health and well-being of himself and of his family, including food, 
8108.Id.
9109.R.  Edward  Freeman  &  John  McVea, A  Stakeholder  Approach to 
Strategic  Management 4  (Darden  Bus.  Sch.  Working Paper  No.  01-02), 
available at http://ssrn.com/abstract=263511.
0110.Id. at 10.
1111.Global  governance  refers  to  voluntary  world-wide  regulatory 
systems. The most notable global governance body is the United Nations, 
but many other intergovernmental organizations provide guidelines, and 
regulations.  See The  Global  Governance  Group, 
http://www.globalgovgroup.com/ (last visited Feb. 16, 2008).
2112.See United  Nations  Global  Compact, 
http://www.unglobalcompact.org/  index.html [hereinafter  Global 
Compact].
3113.Global  Compact,  About  the  Global  Compact,  http://www.unglobal 
compact.org/AboutTheGC/index.html (last visited Feb. 16, 2008).
4114.Global Compact, supra note 112.
5115.Global  Compact,  Human  Rights,  http://www.unglobalcompact.org/ 
Issues/human_rights/index.html (Last visited Feb. 16, 2008).
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clothing, housing, and medical care and necessary social services, 
and the right to security in the event of unemployment, sickness, 
disability  widowhood,  old  age  or  other  lack  of  livelihood  in 
circumstances beyond his control.116
This provision of the UDHR is captured in the principles of 
the UN Global Compact.117
Principles 1 and 2 of the Global Compact originate from 
the  1948 UDHR.  Because  the  UDHR and its  international 
protections  for  individual  human  rights  were  established 
over a half century ago, the principles are now considered 
to be international customary law.118 The objectives of the 
Global  Compact are to  “mainstream the ten principles  in 
business activities around the world, and catalyze actions in 
support  of  UN  goals.”119 The  Global  Compact  does  not 
include  means  to  regulate  the  implementation  of  its 
objectives  and  principles.  The  Global  Compact,  instead, 
“relies  on  public  accountability,  transparency  and  the 
enlightened self-interest of companies, labour [sic] and civil 
society to initiate and share substantive action.”120
The UN also recognizes the need to address AIDS as a 
global  epidemic.  In  particular,  the  UN  focuses  on  the 
severity of the AIDS epidemic in sub-Saharan Africa, where 
seventy-five percent of the world’s population infected with 
AIDS lives.121 Such huge numbers of  people infected with 
AIDS imposes a major economic burden on that part of the 
continent.122
The Declaration  of  Commitment on HIV/AIDS calls  for 
action on a global  scale to address the AIDS epidemic.123 
The Declaration further recognizes the importance of people 
with  AIDS  receiving  the  treatment  that  they  need  by 
6116.Universal Declaration of Human Rights, G.A. Res. 217A (III), U.N. Doc. 
A/810  (Dec.  10,  1948),  available  at http://www.un.org/Overview/rights. 
html [hereinafter UDHR].
7117.See  Global Compact,  supra  note 112 (“Principle 1: Business should 
support and respect the protection of internationally proclaimed human 
rights; and Principle 2: make sure that they are not complicit in human 
rights abuses.”).
8118.Global Compact, Human Rights, supra note 115.
9119.Global  Compact,  What  is  the  UN  Global  Compact?,  http://www. 
unglobalcompact.org/AboutTheGC/index.html (Last visited Feb. 16, 2008).
0120.Id.
1121.Declaration of Commitment on HIV/AIDS, G.A. Res. A/RES/S-26/2, at 1 
(June 27, 2001).
2122.Id. at 2.
3123.Id. at 1.
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emphasizing “that access to medication in the context of 
pandemics  such  as  HIV/AIDS  is  one  of  the  fundamental 
elements  to  achieve  the  full  realization  of  the  right  of 
everyone  to  the  enjoyment  of  the  highest  attainable 
standard of physical and mental health.”124  To implement 
this, and other, principles of the Declaration, the UN calls 
for action not only from international governments, but also 
from the  business  and  civil  sectors  as  well.  Such  action 
includes providing antiviral drugs to treat the disease.125
The  United  Nations  Economic  and  Social  Council  has 
further promulgated principles of CSR in its Norms on the 
Responsibilities  of  Transnational  Corporations  and  Other 
Business Enterprises with Regard to Human Rights.”126 One 
important initial  aspect of  the Norms is  that they require 
multinational corporations (MNCs) to recognize all UN and 
other treaties on human rights, including the World Health 
Organization principles that  recognize health as  a human 
right.127
The principles set forth in the Norms requires MNCs to 
“act  in  accordance with  the fair  business,  marketing and 
advertising practices and shall take all necessary steps to 
ensure  the  safety  and  quality  of  the  goods  and  services 
they provide. . . .”128  This principle further states that MNCs 
shall not “produce, distribute, market, or advertise harmful 
or potentially harmful products for use by consumers.”129
Another aspect of the Norms that provides a model of 
CSR  particularly  helpful  to  effect  change  in  the 
pharmaceutical companies is the definition of stakeholder. 
The definition of stakeholder includes a general category of 
people who are affected by the actions of the MNC.130 The 
definition then elaborates on this general category, noting 
that  stakeholders  can  include  people  or  groups  who  are 
4124.Id. at 3.
5125.Id. at 4.
6126.Norms  on  the  Responsibilities  of  Transnational  Corporations  and 
Other  Business  Enterprises  with  Regard  to  Human  Rights,  U.N.  Doc. 
E/CN.4/Sub.2/2003/12/Rev.2 (2003) [hereinafter Norms].
7127.Id.  at  ¶  4;  World  Health  Organization,  Health  and  Human Rights, 
http://www.who.int/hhr/en/ (last visited Feb. 16, 2008).
8128.Norms,  supra  note  126,  at  §  F(13)  (“Obligations  with  regard  to 
consumer protection”).
9129.Id.
0130.Id. at § I(22).
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directly or indirectly affected by the activities of the MNC.131
2. Organisation for Economic Co-operation and 
Development
The  Organisation  for  Economic  Co-operation  and 
Development (OECD) intends to create a strong system of 
corporate  governance  around  the  world.  Like  the  UN 
Principles  and  Guidelines,  those  of  the  OECD  are  non-
binding,  and  voluntary.132 The  OECD  also  suggests  that 
improved corporate governance will help a business to grow 
and  to  prosper;  it  recognizes  that  business  ethics  and 
awareness of environmental and social concerns will impact 
a company’s long term success.133
The  OECD  principles  provide  a  framework,  or  a 
reference, for legislators or corporations when drafting their 
corporate  governance  model.134 The  principles  are  not, 
however,  a  mandate  to  adopt  any  particular  type  of 
corporate  governance.  The  principles  of  the  OECD  are 
intended to identify objectives of corporate governance and 
create various means for achieving those objectives.135
The  OECD  Principles  state  that  the  board  should 
recognize  the  interests  of  stakeholders,  applying  high 
ethical standards in doing so.136 The OECD recognizes the 
important role of stakeholders in the long term success of 
the  corporation.  The  Principles  state  that  where  a 
stakeholder’s rights are established and protected by law 
the corporation should respect those rights.137 Even in areas 
where stakeholder rights are not legislated, the Principles 
suggest recognition of those broader interests, pointing to 
the  corporation’s  interest  in  maintaining  a  positive 
1131.Principle  22  states  that  the  term  stakeholder  includes  consumer 
groups, customers, and others. Thus, this definition recognizes customers 
of drug companies—those who take the drugs—as people who should be 
protected by the CSR program. Id.
2132.ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT,  OECD GUIDELINES FOR 
MULTINATIONAL ENTERPRISES 17  (2000),  available  at 
http://www.oecd.org/dataoecd/56/36/1922428.pdf  [hereinafter  OECD 
GUIDELINES].
3133.ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT,  OECD PRINCIPLES OF 
CORPORATE GOVERNANCE 12 (2004) available at http:// www.oecd.org/dataoecd/
32/18/31557724.pdf [herinafter OECD PRINCIPLES].
4134.Id. at 11.
5135.Id. at 13.
6136.See generally, OECD PRINCIPLES, supra note 133, at 24–29.
7137.See generally id. at 21.
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reputation.138 The  OECD  omits  from  its  definition  of 
stakeholder, the customer and prospective customer, only 
recognizing  investors,  employees,  creditors,  and 
suppliers.139
The OECD also recognizes the important role that good 
health  and  healthcare  play  in  economic  growth.140 The 
OECD  2007  Annual  Report  mentions  that  insufficient 
healthcare causes unnecessary deaths, and poor health in 
general,  while  recognizing  that  gaps  in  the  access  to 
healthcare  remain  across  socio-economic  groups.141 The 
OECD  views  pharmaceutical  pricing  and  reimbursement 
policies as one cause of low availability and affordability of 
medicine  in  countries  with  need.142 These  policies  are 
viewed  as  an  inhibitors  of  “the  global  public  good  of 
innovation in medicine.”143
Though the OECD Principles do not recognize the same 
definition of a stakeholder as that of the Norms, the OECD 
Guidelines for Multinational Enterprises (MNEs) states that 
they  should  respect  the  human  rights  of  the  individuals 
affected by their activities.144 This recognition is much closer 
to the stakeholder CSR policies the pharmaceuticals should 
adopt,  because  both  customers  and  non-customers  are 
affected by the pharmaceutical companies.145 Furthermore, 
the OECD Guidelines recognize the importance of treating 
consumers in accordance with fair business, marketing, and 
advertising  practices  as  well  as  providing  safe  quality 
goods.146 The  standards  further  state  that  the  products 
should provide enough information to the customer to allow 
an informed decision.147
The OECD Guidelines provide specific goals for MNEs to 
8138.Id.
9139.Id.
0140.ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT, ANNUAL REPORT 47–49 
(2007), available at http://www.oecd.org/dataoecd/1/ 53/38484866.pdf.
1141.Id. at 47.
2142.Id. at 49.
3143.Id.
4144.OECD GUIDELINES, supra note 132, at 19.
5145.As  discussed  in  Part  I,  pharmaceutical  companies  have  a  great 
impact  on  the  health  of  their  customers  as  well  as  the  health  of  sick 
people in poor countries who cannot afford medication for their diseases.
6146.OECD GUIDELINES, supra note 132, at 25.
7147.Id.
MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE AND LEGAL POLICY," 9(2) MINN. J.L. SCI. & 
TECH. 607-636 (2008).
2008] CORPORATE SOCIAL RESPONSIBILITY 629
meet in protecting their customers. The most relevant are 
the health, safety and information standards. One principle 
states  that  MNEs  should  ensure  all  products  meet  the 
required safety standards for health, including appropriate 
product warning labels.148
The  OECD  Principles  provide  helpful  guidance  in  the 
implementation  of  a  corporate  governance  system.  The 
OECD  recognizes  that  corporate  governance  may  be 
implemented  in  various  ways,  either  through  legislation, 
government  regulation,  self  regulation,  or  voluntary 
standards.149 The  first  step  to  implement  the  OECD 
principles is to establish an effective foundation of laws and 
regulations.150 The OECD suggests monitoring the corporate 
governance framework to ensure it is serving its purpose of 
promoting  ethical  and  transparent  corporate  governance 
practices.151 The  OECD  recommends  that  laws  and 
regulations affecting corporate governance be implemented 
efficiently  and  fairly.  One  way  to  achieve  this  is  for 
government  and  regulatory  authorities  to  meet  with 
corporations  and  their  stakeholders  to  assess  the  CSR 
framework of the company.152
While  the  OECD  suggests  self-regulation  as  possible 
means  to  implement  CSR,  it  clearly  prefers  laws  and 
regulations  set  by  a  governing  body.153 Self-regulation  is 
certainly  better  than  no  CSR  at  all,  but  it  can  leave 
stakeholders  and  shareholders  uncertain  about  the 
implementation  and  meaning  of  the  standards.154 This 
uncertainty  contributes  to  the  OECD’s  preference  for 
national regulation that provides a framework shareholders 
and  stakeholders  can  rely  upon,  and  find  redress  in,  if 
something goes wrong.155
3. The European Union
The major publication that sets forth the standards of 
CSR  in  the  EU,  and  the  means  to  implement  those 
8148.Id.
9149.OECD PRINCIPLES, supra note 133, at 29–31.
0150.Id.
1151.Id.
2152.Id.
3153.Id.
4154.Id.
5155.Id.
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standards is the 2001 European Commission Green Paper.156 
The Green Paper recognizes  the stakeholder  approach  to 
CSR, but even more importantly it recognizes customers as 
stakeholders and human rights as an important aspect of 
CSR.  The  Green  Paper  explores  the  role  of  business  in 
issues generally considered to be within the public realm, 
including poverty and exclusion.157
The Green Paper makes ethical treatment of customers 
a part of its Corporate Social Responsibility agenda.158 The 
Green  Paper  touts  this  aspect  of  CSR  as  a  way  to  build 
company  profits.159 By  providing  its  customers  with  safe, 
reliable, high quality products the company will build lasting 
relationships with its customers.160 Of course, these lasting 
relationships are fostered and brought about through the 
CSR program that instilled the ethical values of providing 
top quality products to customers.161
The  Green  Paper  also  discusses  the  importance  of 
recognizing human rights in CSR. Again,  the Green Paper 
points  out  that  recognition  of  human  rights  can  have  a 
positive  economic  effect  for  the  company,  due  to  the 
positive image created.162 Though the human rights section 
focuses primarily on fair labor standards, the Green Paper 
nonetheless  recognizes  the  importance  of  a  corporation 
having less of  a negative impact  on human rights  in the 
local community.163 The Green Paper also incorporates the 
OECD  Guidelines  for  Multinational  Enterprises  which 
establishes standards for protecting the human rights for a 
broader range of stakeholders, including anyone affected by 
the activities of the corporation.164
The  Green  Paper  also  recommends  to  the  MNEs  the 
establishment of codes of conduct to implement its human 
6156.INDUSTRIAL RELATIONS AND INDUSTRIAL CHANGE,  EUROPEAN COMM’N,  GREEN PAPER, 
PROMOTING A EUROPEAN FRAMEWORK FOR CORPORATE SOCIAL RESPONSIBILITY 12, 14 (2001), 
available  at http://ec.  europa.eu/employment_social/soc-
dial/csr/greenpaper_en.pdf [hereinafter GREEN PAPER].
7157.Bantekas, supra note 106, at 317.
8158.GREEN PAPER, supra note 156, at 13–14.
9159.Id.
0160.Id.
1161.Id.
2162.Id. at 14–15.
3163.Id.
4164.Id.; see also OECD GUIDELINES, supra note 132, at 19.
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rights policies.165 A code of  conduct is a set of  standards 
together  with  a  pledge  by  the  company  to  observe  the 
standards.166 To  effectively  implement  human  rights,  the 
codes of conduct must be established at every level of the 
company. A verification scheme should also be established 
to  audit  the  effectiveness  of  the  program.167 The  Green 
Paper suggests that codes of conduct emphasize continuing 
gradual improvements to the standards established by the 
company and to the code of conduct itself.168
III. LESSONS LEARNED: 
IS CSR THE APPROPRIATE PRESCRIPTION?
One  obstacle  to  implementing  CSR  is  the  apparent 
control  the  pharmaceutical  companies  have  over  United 
States lawmakers and regulators. The most recent evidence 
of this control is the failure of the House of Representatives 
to  pass  an  effective  version  of  The  Food  and  Drug 
Administration Amendments Act of 2007.169 This resolution 
was designed to raise the standards for disclosure of drug 
side  effects  and  test  results,  regulate  direct-to-consumer 
advertising, and end conflicts of interest between the FDA 
and  pharmaceutical  companies.170 The  bill  passed  by  the 
House  does  none  of  these  things;  it  strengthens  the 
pharmaceutical  companies’  ties  with  the  FDA.171 This 
reversal occurred as a result of coercion from the powerful 
pharmaceutical lobby, PhRMA.172 The pharmaceutical lobby 
is recognized as the most powerful lobby in Washington.173
5165. GREEN PAPER, supra note 156, at 14-15.
6166.Id.
7167.Id.
8168.Id.
9169.Mike  Adams,  FDA  Tyranny  to  Become  Law:  HR  2900  Analysis,  
NATURALNEWS.COM,  July  12,  2007,  http://www.naturalnews.com/021932.html 
(discussing the passage of Food and Drug Administration Amendments Act 
of 2007, H.R. 2900, 110th Cong. (2007)).
0170.Id.
1171.Id.
2172.Id.
3173.“The combined worth of the world’s top five drug companies is twice 
the combined GDP of all  sub-Saharan Africa and their influence on the 
rules of world trade is many times stronger because they can bring their 
wealth to bear directly on the levers of western power.” Julian Borger, 
Industry  that  Stalks  the U.S.  Corridors of  Power,  GUARDIAN (Manchester), 
Feb.  13,  2001,  available  at 
http://www.guardian.co.uk/international/story/0,3604,437212,00. html.
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Another example of PhRMA’s strength in Washington is 
the failure of The Prescription Drug User Fee Act (PDUFA) 
that  was  intended  to  strengthen  the  FDA  system  of 
approving drugs.174 Instead the law created a sense that the 
FDA is actually accountable to the drug companies, which 
results in less drug safety regulation.175 Additionally, PDUFA 
has minimal funding and this limits the FDA’s testing and 
research of drug safety.176 Not only does this legislation not 
help to regulate drug safety, but commentators argue that 
the Act has the opposite effect.177
I raise these issues here to demonstrate the difficulties 
that lie ahead in mandating the adoption of CSR principles 
in pharmaceutical companies. To pass the laws establishing 
CSR  guidelines,  legislators  will  have  to  overcome  the 
pharmaceutical  lobby.  With  enough  ground  swell  and 
consumer support  for new CSR principles,  PhrMA may be 
forced  to  consider  the  negative  impact  that  opposing 
human rights  and consumer protection laws will  have on 
public opinion of drug companies.
A. CSR APPLIED TO PHARMACEUTICAL COMPANIES
There are two fundamental aspects of CSR to consider 
in examining the various models capable of addressing the 
problems  identified  with  the  pharmaceutical  companies: 
who the CSR protects, and what rights CSR protects. The 
appropriate model of CSR will protect both customers and 
non-customers. CSR should protect human rights of these 
groups specifically recognizing that health is a human right.
The  pharmaceutical  companies  must  recognize 
stakeholders,  not just shareholders. Adopting a system of 
CSR that recognizes and protects the stakeholders will shift 
pharmaceutical  companies  from  the  current  bottom  line 
4174.Sidney  Wolfe,  Ben  Peck  &  Frank  Clemente,  Comments  on:  The 
Prescription Drug User Fee Act (PDUFA), PUBLIC CITIZEN, Jan. 25, 2002,  http://
www.citizen.org/publications/release.cfm?ID=7145.
5175.Avorn, supra note 53.
6176.The FDA proposed to devote only $29.3 million to the drug-safety 
program. This amounts to 6.7% of the $437.8 million in user-fee revenue. 
Compare this to the $188.5 billion that was spent on prescription drugs in 
the United States in 2004, and the $11.9 billion spent on pharmaceutical 
advertising. Sean Hennessy & Brian L. Strom,  PDUFA Reauthorization—
Drug Safety’s Golden Moment of Opportunity?, 356 NEW ENG. J. MED. 1703, 
1703 (2007).
7177.Id.
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model to that of ethics and human rights. The stakeholder 
model  implemented  must  recognize  both  customers  and 
individuals  affected  by  the  companies’  activities  as 
stakeholders.  The  broadest  recognition  of  a  stakeholder 
group is  found in  the OECD Guidelines which states  that 
MNC’s should respect the human rights of those affected by 
their activities.178 This broad interpretation of a stakeholder 
includes the groups  of  people  who need to be protected 
from the  pharmaceutical  companies,  both  customers  and 
poor people who cannot afford to be customers.
When it  comes to the issues discussed in Part I,  it  is 
clear that the concern is to help customers, in addition to 
people who need a medicine, but who do not have access to 
it.  Customers  need  protection  from  side  effects,  over-
prescription, and direct-to-consumer advertising. Those who 
desire medication need to gain access  to the drugs they 
need in order to live. The OECD’s broad recognition covers 
these groups and makes for  a good starting point for  an 
appropriate model of CSR.
Both the Norms and the OECD Guidelines establish a 
requirement  that  a  corporation  conduct  its  business 
recognizing  fair  business,  marketing  and  advertising 
practices, and that companies should provide safe quality 
products to their customers.179 This principle addresses the 
protection  of  the  customer.  Application  of  this  principle 
could  be  used  to  limit  direct-to-consumer  advertising, 
require  fewer  harmful  side  effects  or  increased  patient 
notification  regarding  side  effects,  and  create  more 
stringent prescription standards to ensure the benefit to the 
patient outweighs the potential risks.
In the face of a fair advertising requirement, direct-to-
consumer  advertising  will  either  undergo  a  fundamental 
change,  or  end  altogether.  Many  do  not  consider  this 
advertising to be fair due to its effects on the consumer and 
prescription  practices.180 CSR  principles  should  make 
advertising more fair. Direct-to-consumer advertising would 
be  acceptable  as  long  as  it  was  considered  fair  to  the 
consumer.  These  advertisements  would  have  to  be 
8178.OECD GUIDELINES, supra note 132, at 19.
9179.Id.; Norms, supra note 126.
0180.Direct-to-consumer advertising may encourage patients to pressure 
their physicians to prescribe specific medications. Wilkes et al., supra note 
76, at 120.
MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE AND LEGAL POLICY," 9(2) MINN. J.L. SCI. & 
TECH. 607-636 (2008).
634 MINN. J.L. SCI. & TECH. [Vol. 9:2
subjected  to  a  heightened  standard  to  ensure  that  they 
were  not  misleading  and  did  not  lead  to  self  diagnoses. 
Overall,  the goal  of  the advertising should be to improve 
patient  health,  not  to  improve  the  shareholders’  bottom 
line.  This  goal  is  consistent  with  not  only  the  fairness 
standard found in the OECD Guidelines and the Norms, but 
also  with  the  standards  of  fair  business  practices  and 
providing safe quality products to consumers.
Additionally,  by  requiring  safe  quality  products,  the 
consumer is  protected from dangerous prescriptions.  This 
would  call  for  higher  regulatory  standards  to  ensure  the 
drug’s side effects did not outweigh its benefits. The CSR 
model  could  implement  such  regulatory  standards.  A 
standard  could  focus  on  informing  patients  about  risks, 
creating  a  heightened scrutiny  of  the  risks  of  taking  the 
drug,  and  weighing  the  risks  against  the  benefits.  By 
requiring  such  a  standard,  the  patient  would  be  better 
informed  of  the  risks  associated  with  the  drug,  and  the 
pharmaceutical companies would have less influence over 
the doctors’ prescriptions. This would have a chilling effect 
on  over-prescription  and  lead  to  overall  consumer 
protection.
The  CSR program should  also  protect  those  who  are 
affected by the activities of the pharmaceutical companies 
but are not customers. Those affected by the activities of 
the company are recognized as stakeholders in the various 
models of CSR. This includes those who need drugs but do 
not have access to them either because the drugs are too 
expensive or because the needed treatments have become 
ineffective. This group includes the AIDS patients in Brazil 
and  South  America,  the  people  who  suffer  from  tropical 
diseases in Africa like sleep sickness, and the boy in India 
whose family could not afford the medicine to save him. The 
activities  of  the  pharmaceutical  companies  affect  these 
people because the pharmaceutical companies control the 
means to make them healthy and to save their lives. This 
profound  effect  on  these  non-customers’  lives  qualifies 
these  people  as  affected  by  the  activities  of  the 
pharmaceutical companies.
Non-customers are recognized as stakeholders to whom 
the  pharmaceutical  companies  owe  a  duty,  and  thus 
companies  should  provide  protection  for  these  people. 
Coupling this recognition of non-customers as stakeholders 
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with the human rights aspect of  CSR truly protects these 
people. The human rights aspect of CSR includes the right 
to health and to medicine as established in both the UDHR 
and  the  WHO  Health  and  Human  Rights  section.181 The 
recognition of the right to health and medicine as a human 
right will compel the pharmaceutical companies to protect 
those rights by providing treatment to those who need it. 
Thus, the pharmaceutical  companies would,  through CSR, 
protect  human  rights  including  the  right  to  health  and 
medicine. The human rights aspect of CSR coupled with the 
broad  definition  of  a  stakeholder,  which  includes  non-
customers,  would  effectively  require  the  pharmaceutical 
companies  to  find  a  way  to  provide  low  cost,  effective 
medicine to those who could not otherwise afford it.
B. CHALLENGES TO IMPLEMENTING CSR
The  hurdle  in  the  CSR  debate  is  not  whether  the 
principles would work to cure the issues raised in Part I, as 
the  discussion  above  shows  that  those  issues  would  be 
effectively addressed through adopting the CSR principles. 
The hurdle is  how to implement the principles.  All  of  the 
CSR models discussed are voluntary. They suggest means 
of  implementation,  such as adopting codes of  conduct or 
adhering to the laws of the host country, but they do not 
establish a way to mandate CSR in a country that does not 
recognize  CSR  in  its  corporate  governance.  It  would  be 
especially difficult to establish CSR as a mandatory law that 
applies to companies that have a powerful lobby and will 
fight the regulation.
The CSR rules that are applicable to the pharmaceutical 
companies must be mandatory. If they are voluntary, it is 
likely that  the pharmaceutical  companies  will  continue to 
value  shareholder  wealth  over  stakeholder  health.  As 
alluded  to  in  describing  HR  2900  and  PDUFA,  the 
pharmaceutical companies have an aversion to regulations. 
If CSR principles were promulgated, but voluntary, it seems 
likely that the pharmaceutical companies would not adopt a 
CSR program. Therefore, CSR must be mandatory.
1181.UDHR,  supra note  116;  World  Health  Organization,  Health  and 
Human Rights, http://www.who.int/hhr/en/ (last visited Feb. 28, 2008).
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CONCLUSION
Pharmaceutical company actions can be harmful to both 
their customers, by over-prescription, harmful side effects, 
and direct-to-consumer advertising, and to non-customers, 
by these people not having access to needed treatment or 
the treatment that they do have being ineffective. Models of 
CSR address these issues, and through a model of CSR that 
incorporates the principles discussed above, the harms of 
the pharmaceutical companies could be cured. The major 
challenge to  implementing  a  CSR program to  cure  these 
issues is the powerful pharmaceutical lobby in Washington.
One  potential  way  to  encourage  companies  to  adopt 
CSR would  be  for  the  United  States  Government  to  give 
corporate  tax  benefits  for  implementing  CSR.182 Such  a 
voluntary  program  would  strike  a  balance  between  the 
shareholder-oriented  approach  and  the  stakeholder 
approach.  The  shareholders  would  benefit  in  that  the 
corporation received favorable tax incentives. Stakeholders 
would benefit from the implementation of CSR. Though such 
a means of  implementing CSR is  not mandatory it  would 
create  motivation  for  pharmaceutical  companies  to 
implement CSR.
Added  motivation  for  pharmaceutical  companies  to 
further increase CSR beyond what is adopted for tax breaks 
would then come from the market. If consumers began to 
buy products from the companies that implemented CSR, 
the market  would drive further implementation of  CSR.183 
Such  increased  popularity  in  the  market  would  drive  up 
sales and result in increased profits to benefit shareholders. 
Thus, CSR would not only benefit stakeholders, but it would 
also benefit shareholders.
2182.Similar  tax incentives already exist  for  encouraging environmental 
friendly  corporate  practices.  See  generally 26  U.S.C.  §  179D  (2000) 
(deduction available for energy efficient commercial buildings); 26 U.S.C. § 
48 (2000) (tax credit available for use of solar and other renewable energy 
sources).
3183.A  study  found  that  roughly  70%  of  the  people  polled  found  a 
company’s public health impact important vs.  about 40% who found it 
important  for  a  company to  deliver  value to its  shareholders.  FLEISHMAN-
HILLARD INT’L COMMC’NS, RETHINKING CORPORATE SOCIAL RESPONSIBILITY 8–10  (2006), 
available at http://www.csrresults.com/FINAL_Full_Report.pdf
